NUPLEX: A Plasma Epigenome Profiling Platform for Diagnostics and Precision Medicine

Important results from the project

Epigenetics is seen as on of the next revolution in healthcare. Understanding of epigenetic mechanisms is crucial for advancing, among other things, cancer diagnostics, biomarker discovery, drug development and precision medicine. Within this project, Epigenica AB will develop its proprietary epigenetic profiling platform for liquid biopsies.

Expected long term effects

Epigenica´s platform technology, developed into kit and service offerings will enable clinical researchers to profile - quantitatively and in high throughput - epigenetic features in liquid biopsies, discovering new disease associated biomarkers. It will inform drug developers and clinicians to develop personalized treatments. Ultimately, it will contribute to better treatment choices and better outcomes for patients. Positive PoC study performed on a small set of ovarian cancer patients giving confidence to continue with a larger set of samples in a larger follow up study.

Approach and implementation

In the project, an EIC Transition application was prepared, building on a prior ERC Proof of Concept grant awarded to Epigenica. The Vinnova funding was used to produce valuable preliminary PoC data, support writing an application including a fine-grained project plan and budget as well as submit an application to the EIC transition call.